ATE167859T1 - ANTIPROLIFERATIVE 4H-NAPHTHO(1,2-B)PYRANE DERIVATIVES - Google Patents

ANTIPROLIFERATIVE 4H-NAPHTHO(1,2-B)PYRANE DERIVATIVES

Info

Publication number
ATE167859T1
ATE167859T1 AT92309169T AT92309169T ATE167859T1 AT E167859 T1 ATE167859 T1 AT E167859T1 AT 92309169 T AT92309169 T AT 92309169T AT 92309169 T AT92309169 T AT 92309169T AT E167859 T1 ATE167859 T1 AT E167859T1
Authority
AT
Austria
Prior art keywords
alkyl
phenyl
optionally substituted
hydroxy
carboxy
Prior art date
Application number
AT92309169T
Other languages
German (de)
Inventor
Colin Peter Dell
Colin William Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919121358A external-priority patent/GB9121358D0/en
Priority claimed from GB929213058A external-priority patent/GB9213058D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE167859T1 publication Critical patent/ATE167859T1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/92Naphthopyrans; Hydrogenated naphthopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

A pharmaceutical compound of the formula <CHEM> in which n is 0, 1 or 2 and R<1> is attached at any of the positions 5, 6, 7, 8, 9 or 10, and each R<1> is halo, trifluoromethyl, C<5> PI <8> alkoxy, hydroxy, nitro, C<5> PI <8> alkyl, C<5> PI <8> alkylthio, hydroxy-C<5> PI <8> alkyl, hydroxy-C<5> PI <8> alkoxy, trifluoromethoxy, carboxy, -COOR5 where R5 is an ester group, -CONR6R7 or -NR6R7 where R6 and R7 are each hydrogen or C<5> PI <8>alkyl; R<2> is phenyl, naphthyl or heteroaryl selected from thienyl, pyridyl, benzothienyl, quinolinyl, benzofurangyl or benzimidazolyl, said phenyl, naphthyl and heteroaryl groups being optionally substituted, or R<2> is furanyl optionally substituted with C<5> PI <8> alkyl; R<3> is nitrile, carboxy, -COOR8 where R8 is an ester group, -CONR9R<1>0 where R9 and R<1>0 are each hydrogen or C<5> PI <8> alkyl, or R<1><1>SO<6>- where R<1><1> is C<5> PI <8> alkyl or optionally substituted phenyl; and R4 is -NR<1><2>R<1><3>, -NHCOR<1><2>, -N(COR<1><2>)<6> or -N=CHOCH<6>R<1><2> where R<1><2> and R<1><3> are each hydrogen or C<5> PI <8> alkyl optionally substituted with carboxy, <CHEM> where X is C<6> PI <8> alkylene, or -NHSO<6>R<1>4 where R<1>4 is C<5> PI <8> alkyl or optionally substituted phenyl; provided that when n is 0, R<3> is nitrile and R4 is -NH<6>, R<2> is not phenyl or phenyl substituted in the para-position with a single chloro, hydroxy or methoxy substituent; and salts thereof. este
AT92309169T 1991-10-09 1992-10-08 ANTIPROLIFERATIVE 4H-NAPHTHO(1,2-B)PYRANE DERIVATIVES ATE167859T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919121358A GB9121358D0 (en) 1991-10-09 1991-10-09 Pharmaceutical compounds
GB929213058A GB9213058D0 (en) 1992-06-19 1992-06-19 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ATE167859T1 true ATE167859T1 (en) 1998-07-15

Family

ID=26299655

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92309169T ATE167859T1 (en) 1991-10-09 1992-10-08 ANTIPROLIFERATIVE 4H-NAPHTHO(1,2-B)PYRANE DERIVATIVES

Country Status (22)

Country Link
US (1) US5284868A (en)
EP (1) EP0537949B1 (en)
JP (1) JPH05194477A (en)
KR (1) KR100228841B1 (en)
CN (1) CN1034938C (en)
AT (1) ATE167859T1 (en)
AU (1) AU658003B2 (en)
CA (1) CA2079428A1 (en)
CZ (1) CZ281688B6 (en)
DE (1) DE69226060T2 (en)
DK (1) DK0537949T3 (en)
ES (1) ES2117035T3 (en)
FI (1) FI924551A (en)
HU (1) HU218916B (en)
IL (1) IL103356A (en)
MX (1) MX9205714A (en)
MY (1) MY111368A (en)
NO (1) NO301587B1 (en)
NZ (1) NZ244627A (en)
PH (1) PH30659A (en)
RU (1) RU2071472C1 (en)
TW (1) TW221292B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
EP0599514A3 (en) * 1992-11-18 1994-07-06 Lilly Industries Ltd Pyranoquinoline derivatives as inhibitors of cell proliferation.
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds
EP0619314A1 (en) * 1993-04-09 1994-10-12 Eli Lilly And Company 4-Phenyl-4H- naphtho(2,1-b)pyran derivatives and their pharmaceutical use
WO1995008289A2 (en) * 1993-09-16 1995-03-30 Scimed Life Systems, Inc. Percutaneous repair of cardiovascular anomalies and repair compositions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
CN1219872A (en) * 1996-05-24 1999-06-16 血管技术药物公司 Compositions and method for treating or preventing diseases of body passageways
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
ATE260269T1 (en) 1999-11-05 2004-03-15 Cytovia Inc SUBSTITUTED 4H-CHROMENS AND SIMILAR COMPOUNDS AS KASPASIS ACTIVATORS AND APOPTOSIS INDUCTORS AND THE USE THEREOF
EP1392683B1 (en) * 2001-05-16 2009-12-02 Cytovia, Inc. Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and their use as anticancer agents
EP1392283A4 (en) 2001-05-16 2004-10-20 Cytovia Inc Substituted coumarins and quinolines as caspase activators
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1513515A2 (en) * 2002-05-16 2005-03-16 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1509515A4 (en) * 2002-05-16 2006-07-05 Cytovia Inc Substituted 4-aryl-4h-pyrrolo 2,3-h chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20040127519A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
US20040127511A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
NZ553688A (en) * 2004-09-09 2011-05-27 Florey Howard Inst Enzyme inhibitors for the inhibition of insulin-regulated aminopeptidase
EP2532388A3 (en) * 2005-02-16 2013-03-06 Md Bioalpha Co., Ltd. Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
US20080183282A1 (en) * 2006-03-09 2008-07-31 Saul Yedgar Use of lipid conjugates for the coating of stents and catheters
US8263775B2 (en) 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
EA015364B1 (en) * 2009-03-18 2011-06-30 Учреждение Российской Академии Наук Институт Элементоорганических Соединений Им. А.Н. Несмеянова Ран (Инэос Ран) 6,6'-diisopropyl-8,8'-dimethyl-2,2'-dinitro-3,3'-bis(trifluoromethyl)-3h,3'h-[9,9']di[benzo(f)chromenyl]-5,10,5',10'-tetraole, inhibiting antitumor activity and a method for preparing thereof
WO2012062901A2 (en) * 2010-11-12 2012-05-18 Deutsches Krebsforschungszentrum (Dkfz) Chromene derivatives and their analoga as wnt pathway antagonists
WO2013070998A1 (en) 2011-11-10 2013-05-16 Memorial Sloan-Kettering Cancer Center TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU724509A1 (en) * 1978-09-21 1980-03-30 Пермский государственный фармацевтический институт Method of preparing 2-aroyl-3h-naphtho/2,1-b/pyranones-3
US5232942A (en) * 1988-04-14 1993-08-03 Yamanouchi Pharmaceutical Co., Ltd. Q-2819 substance and the use thereof

Also Published As

Publication number Publication date
EP0537949A1 (en) 1993-04-21
NO923910D0 (en) 1992-10-08
KR100228841B1 (en) 1999-11-01
CZ281688B6 (en) 1996-12-11
ES2117035T3 (en) 1998-08-01
CA2079428A1 (en) 1993-04-10
PH30659A (en) 1997-09-16
NO923910L (en) 1993-04-13
TW221292B (en) 1994-02-21
MX9205714A (en) 1993-04-01
CZ303592A3 (en) 1993-12-15
MY111368A (en) 1999-12-31
IL103356A0 (en) 1993-03-15
EP0537949B1 (en) 1998-07-01
DK0537949T3 (en) 1999-02-15
IL103356A (en) 1998-02-22
HU218916B (en) 2000-12-28
AU2621692A (en) 1993-04-22
NZ244627A (en) 1994-12-22
FI924551A0 (en) 1992-10-08
HUT62281A (en) 1993-04-28
KR930007931A (en) 1993-05-20
JPH05194477A (en) 1993-08-03
DE69226060T2 (en) 1998-11-19
DE69226060D1 (en) 1998-08-06
NO301587B1 (en) 1997-11-17
CN1073437A (en) 1993-06-23
AU658003B2 (en) 1995-03-30
RU2071472C1 (en) 1997-01-10
CN1034938C (en) 1997-05-21
US5284868A (en) 1994-02-08
FI924551A (en) 1993-04-10
HU9203183D0 (en) 1992-12-28

Similar Documents

Publication Publication Date Title
ATE167859T1 (en) ANTIPROLIFERATIVE 4H-NAPHTHO(1,2-B)PYRANE DERIVATIVES
CO5150224A1 (en) TRIAZOL COMPOUNDS AND ITS USE
DK0765314T3 (en) Benzoheterocyclic derivatives which can be used as vasopressin or oxytocin modulators
NO983099D0 (en) New retroviral protease inhibitors
FI913782A (en) ISOXAZOLDERIVAT.
DK0641325T3 (en) Inhibitors of retroviral protease
DK0444659T3 (en) Pharmaceutical solution containing derivatives of FK 506
EA199800466A1 (en) Substituted derivative of aminocycloalkylpyrrolidone
RS51296B (en) Novel cyclohexil sulphones
MY109777A (en) Pharmaceutical compounds therewith
FI911138A (en) NY SUBSTITUERAD AMINFOERENING OCH FOERFARANDE FOER DESS FRAMSTAELLNING.
DK0639173T3 (en) Certain 2- (2&#39;-methyl-3 &#39;, 4&#39;-trisubstituted benzoyl) -1,3-cyclohexanedione
DE69113893D1 (en) 6,7-disubstituted 2-aminotetralins as immunomodulators and pharmaceutical compositions thereof.
FI904449A0 (en) N-AZASICYCLO / 3.3.0 / OCTANAMIDER AV AROMATISKA SYROR.
DK0532126T3 (en) Heterocyclic derivatives of alkoxy acrylates with fungicidal activity
MX9204939A (en) INHIBITORS 5-BIS-AMINOMETILEN-1,3-DIOXAN-4,6-DIONA N, N &#39;, N&#39;-TRISUBSTITUIDAS, DE LA ACIL COENZIMA A: CHOLESTEROL-ACILTRANSFERASA.
ATE154243T1 (en) BLOOD VESSEL HYPERTROPHY INHIBITOR
TH17774EX (en) A new type of 1,3-oxacin-4-transfer derivative. Herbicides containing these derivatives and antimicrobial agents for treating these derivatives.
TH6968A (en) Triopstite 1,3,5-triazine 2,4,6-triion

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee